Supplementary Figure 1 from Defining Key Signaling Nodes and Therapeutic Biomarkers in <i>NF1</i>-Mutant Cancers
Clare F. Malone(Arup Group (United States)), Karen Cichowski(Brigham and Women's Hospital), Rachel Ingraham(Brigham and Women's Hospital), Ophélia Maertens(American Institutes for Research)
Cited by 0
Related Papers
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
|Cell|2015|377
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
|Cancer Discovery|2012|297
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
|Cancer Cell|2011|259
Elucidating Distinct Roles for <i>NF1</i> in Melanomagenesis
|Cancer Discovery|2012|250
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients
|Human Molecular Genetics|2006|213